Strategic Energy Resources Limited (SER)

Market Closed

CXA

- Market Cap

- P/E Ratio

0% Div Yield

1,000,123 Volume

- Eps

Want to track SER and more in your Portfolio? 🎯

Get Started For Free

Summary

SER closed yesterday higher, an increase of 0% from Wednesday's close, completing a monthly decrease of -25%. Over the past 12 months, SER stock lost -14.29%.

SER is not paying dividends to its shareholders.

The last earnings report, released on Nov 10, 2025, exceeded the consensus estimates by 0.02%. On average, the company has fell short of earnings expectations by -0.07%, based on the last three reports.

The stock of the company had never split.

The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on AMEX (USD).

Overview
Earnings
News

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

Seres Therapeutics's VOWST divestiture injected cash, retired debt, and refocused the company as a clinical‑stage microbiome specialist. Their current lead candidate is SER‑155, which seems to reduce bloodstream infections up to 77% according to their Phase 1b trial. SER-155 also holds the FDA's Breakthrough and Fast Track designations. MCRB targets more interim Phase 2 SER‑155 data within 12 months.

Seekingalpha | 4 months ago

Strategic Energy Resources Limited (SER) FAQ

On which exchange is it traded?

Strategic Energy Resources Limited is listed on AMEX.

What is its stock symbol?

The ticker symbol is SER.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

Has Strategic Energy Resources Limited ever had a stock split?

No, there has never been a stock split.

Strategic Energy Resources Limited Profile

Biotechnology Industry	Healthcare Sector	Mr. Steven A. Ledger CEO	CXA Exchange	US81751A1088 ISIN
United States Country	9 Employees	- Last Dividend	15 Mar 2024 Last Split	- IPO Date

Overview

Serina Therapeutics, Inc. is a pioneering biotechnology firm grounded in Huntsville, Alabama, focused on formulating innovative drug therapies for neurological diseases and pain management. Established in 2006, the company has been at the forefront of developing novel treatments utilizing its proprietary POZ technology. This cutting-edge approach is aimed at enhancing drug delivery, targeting persistent health issues like Parkinson's disease, epilepsy, and providing long-lasting pain relief solutions. Moreover, Serina Therapeutics, Inc. extends its technological advancements into the realm of infectious disease prevention by developing lipid nanoparticle delivered ribonucleic acid (RNA) vaccines, showcasing its versatility in the fast-evolving biotech landscape.

Products and Services

SER 252: A POZ conjugate designed specifically for treating Parkinson's disease. SER 252 exemplifies the company's commitment to combating neurological disorders by targeting the underlying causes of this debilitating condition.
SER 227: This product is focused on long-acting pain relief. SER 227 represents Serina Therapeutics' venture into pain management, promising a novel approach to long-term pain management strategies.
SER 214: Another pioneering treatment aiming to tackle Parkinson's disease, SER 214 underscores the company's dedication to addressing this challenging neurological disorder through innovative therapeutic interventions.
SER 228: In the fight against epilepsy, SER 228 is being developed as a groundbreaking treatment option. Through this product, Serina Therapeutics, Inc. endeavors to provide effective solutions to those living with epilepsy.
POZ Technology in Lipid Nanoparticle Delivered Ribonucleic Acid (RNA) Vaccines: Apart from neurological and pain management solutions, the company is also making strides in protecting against infectious diseases through the development of RNA vaccines. This initiative highlights its adaptability and foresight in leveraging its POZ technology for broader medical applications, particularly in the area of infectious diseases prevention.